由嚴重急性呼吸道症候群冠狀病毒2 型(severe acute respiratory syndrome coronavirus 2) 所造成之2019年新型冠狀病毒感染症(coronavirus disease 2019) 是一種先前未被發現並具有高度感染力的病毒性疾病，業已引發了全球性感染的危機。糖尿病控制不佳已被認為是2019 年新型冠狀病毒感染症之預後不良的一個關鍵性危險因子。2019 年新型冠狀病毒感染症會導致嚴重代謝功能失常、新發糖尿病與在內皮細胞功能異常的背景下所增加的血栓事件。目前有具體證據顯示當高血糖與其相關危險因子交互作用之下，將導致免疫系統與發炎反應的改變，如此一來，將使得個體容易感染到嚴重的2019 年新型冠狀病毒感染症因而導致結果的惡化，其中包括有較高的死亡率在內。除了降血糖的作用之外，在感染2019 年新型冠狀病毒感染症期間，抗糖尿病藥的多樣性效應(pleiotropic effects) 能夠抑制病毒的活動、減輕內皮細胞功能的異常、緩解氧化效應和調解發炎與免疫系統的反應。這些作用使得抗糖尿病藥被重新思考使用作為糖尿病人感染2019年新型冠狀病毒感染症後之選擇用藥，用以對抗嚴重急性呼吸道症候群冠狀病毒2 型所引起的海嘯。本篇綜論旨在探討糖尿病與2019 年新型冠狀病毒感染症之間的關聯和這個疾病的病生理學對糖尿病的影響以及施用抗糖尿病藥對於糖尿病人當前2019 年新型冠狀病毒感染症流行期間的潛在治療效果。鑒於人類感染嚴重急性呼吸道症候群冠狀病毒2 型的短暫歷程，使得近期相關之研究所提供的資訊是有其受限制的。因此，進一步探討糖尿病人在感染2019年新型冠狀病毒感染症之後的最適當的血糖管理是有其必要性的。

The coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a previously unrecognized viral illness with high infectivity that has sparked a global crisis. Poorly controlled diabetes was demonstrated to be a crucial risk factor for poor COVID-19 outcomes. COVID-19 infections are associated with severe metabolic dysfunctions, new-onset diabetes, and increased thrombotic events against the backdrop of aberrant endothelial function. The current body of evidence suggests that when hyperglycemia interacts with other risk factors, it might modify immune and inflammatory responses such that individuals become susceptible to severe COVID-19 infection and worse outcomes including higher mortality. Apart from their glucose-lowering actions, the pleiotropic effects of antidiabetic medications can inhibit viral action, attenuate endothelial dysfunction, ameliorate oxidant effects, and modulate inflammatory and immune responses during COVID-19 infections. These actions make antidiabetic medications feasible candidates for drug repurposing to combat the SARS-CoV-2-induced tsunami in diabetic COVID-19 patients. This review discusses the association between diabetes and COVID-19, pathophysiology of the disease in diabetes, and therapeutic potential of antidiabetic medications for diabetic patients during the current COVID-19 pandemic. Given the short history of human infection with SARS-CoV-2, the information provided by recent studies is limited. Hence, further investigations of the optimal management of patients with diabetes who are affected by COVID-19 are warranted.